Changes in Lipid Profiles and Safety of Raltegravir Based Antiretroviral Therapy in HIV-1-Infected Patients With Hyperlipidemia While on Current Standard Therapy.
Phase of Trial: Phase III
Latest Information Update: 14 Nov 2014
At a glance
- Drugs Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics; Registrational
- 16 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 29 Oct 2013 Planned end date changed from 1 Jun 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 22 Apr 2013 Planned end date changed from 1 Dec 2011 to 1 Jun 2013 as reported by ClinicalTrials.gov.